Fluence Bioengineering

MedTech

Seegene | February 01, 2021

South Korea's biotechnology firm Seegene (KQ096530) said Monday it built up the world's first COVID-19 diagnostic variation test, fit for screening COVID-19 and recognizing various mutant variations in a single reaction. Seegene's new variation test, the 'Allplex™ SARS-CoV-2 Variants I Assay,' can detect and separate virus variations, including those discovered to be more contagious and fatal. The new variation test identifies COVID-1...

Medical

Ebanga | December 29, 2020

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...

Cell and Gene Therapy

Moderna | December 14, 2021

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vacci...

Industrial Impact

Willow Biosciences Inc. | February 01, 2022

Willow Biosciences Inc. a leading biotechnology company that manufactures pure, consistent and sustainable cannabinoids via yeast biosynthesis, announced that it will host a webcast investor presentation on Thursday, February 3rd at 2:00 PM EST. During the webcast, Willow's President and Chief Executive Officer Trevor Peters will provide a presentation through a PowerPoint discussion that will cover key areas of Willow's business. After the formal presentation, investors w...